Press release
Orthofix and MTF Biologics Expand Partnership Agreement
LEWISVILLE, Texas--(BUSINESS WIRE)-- Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced
About this update from Orthofix Medical Inc.
[{"type":"text","content":" LEWISVILLE, Texas--(BUSINESS WIRE)--\nOrthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the renewal and expansion of its partnership agreement with MTF Biologics – a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. The collaboration extends Orthofix’s exclusive marketing rights to the Trinity™ allograft line through 2032 and includes an expansion agreement for the development of a demineralized bone matrix (DBM) that Orthofix will market under the Legacy™ brand name.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220503005524/en/The Legacy™ demineralized bone matrix expands and complements the Orthofix line of biologic solutions for spine and orthopedic surgical applications. (Photo: Business Wire)\n“Together Orthofix and MTF Biologics have a long history of bringing advanced biologic solutions to the market, with more than 350,000 patients receiving their Trinity allografts,” said Orthofix President of Global Spine Kevin Kenny. “This agreement solidifies our partnership with MTF Biologics as the sole provider of MTF allograft offerings. The addition of the Legacy demineralized bone line will expand our biologic portfolio, increasing the options available and offering a value solution for our customers and their patients.”\n\n“MTF Biologics is pleased to strengthen our exclusive partnership with Orthofix to continue our joint investments in innovative solutions, and the provision of Trinity Elite™ and Trinity Evolution™ allografts,” said Joe Yaccarino, President and CEO MTF Biologics. “This agreement aligns with MTF Biologics’ mission of honoring donor families by serving patients who are in need of grafts and innovative allograft solutions to aid them on their road to recovery.”\n\nThe Legacy DBM will be a complementary addition to the Orthofix demineralized bone line which consists of FiberFuse™ Advanced and FiberFuse Strip, both also provided by MTF Biologics. A demineralized cortical bone powder with a sodium hyaluronate carrier, the Legacy DBM will be applicable in spine and orthopedic procedures. The Parties expect to make the Legacy DBM available to customers starting in the third quarter of 2022.\n\nOrthofix recogn...